Kcna2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@niday2022] <span class="infobox-title">KCNA2 Gene</span> [@pan2021] | Property | Value | [@brewster2020] |----------|-------| [@liu2019] | Gene Symbol | KCNA2 | | Full Name | Potassium Voltage-Gated Channel Subfamily A Member 2 (Kv1.2) | | Chromosomal Location | 1p13.3 | | NCBI Gene ID | 3737 | | OMIM ID | 176266 | | Ensembl ID | ENSG00000177301 | | UniProt ID | P16389 | | Associated Diseases | Epilepsy, Ataxia, Intellectual Disability, Neuromuscular Disorders | </div>
Overview
KCNA2 (Potassium Voltage-Gated Channel Subfamily A Member 2) encodes the Kv1.2 potassium channel, a voltage-gated potassium channel important for neuronal excitability. Kv1.2 is one of the most abundant potassium channels in the brain and is essential for repolarizing [neurons](/entities/neurons) after action potentials. Mutations in KCNA2 cause a spectrum of neurological disorders including epilepsy, ataxia, and intellectual disability, making it an important target for understanding neuronal excitability disorders.
Normal Function
...
KCNA2 Gene
Introduction
Kcna2 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@niday2022] <span class="infobox-title">KCNA2 Gene</span> [@pan2021] | Property | Value | [@brewster2020] |----------|-------| [@liu2019] | Gene Symbol | KCNA2 | | Full Name | Potassium Voltage-Gated Channel Subfamily A Member 2 (Kv1.2) | | Chromosomal Location | 1p13.3 | | NCBI Gene ID | 3737 | | OMIM ID | 176266 | | Ensembl ID | ENSG00000177301 | | UniProt ID | P16389 | | Associated Diseases | Epilepsy, Ataxia, Intellectual Disability, Neuromuscular Disorders | </div>
Overview
KCNA2 (Potassium Voltage-Gated Channel Subfamily A Member 2) encodes the Kv1.2 potassium channel, a voltage-gated potassium channel important for neuronal excitability. Kv1.2 is one of the most abundant potassium channels in the brain and is essential for repolarizing [neurons](/entities/neurons) after action potentials. Mutations in KCNA2 cause a spectrum of neurological disorders including epilepsy, ataxia, and intellectual disability, making it an important target for understanding neuronal excitability disorders.
Normal Function
KCNA2/Kv1.2 functions as:
Voltage-gated potassium channel: Permits K+ efflux during repolarization
Neuronal excitability regulator: Controls action potential shape and frequency
Axonal conduction: Important for saltatory conduction in myelinated axons
Synaptic integration: Modulates presynaptic release and postsynaptic responses
Network oscillation builder: Contributes to gamma and theta oscillations
Biophysical Properties
Kv1.2 channels are characterized by:
Delayed rectifier: Activates with depolarization, typical activation threshold -10 to +10 mV
Medium to slow inactivation: C-type inactivation mechanism
High conductance: Efficient K+ flux, conductance ~10-15 pS
Modulation: Regulated by phosphorylation, alternative splicing, and auxiliary subunits
Channel Complex Assembly
Kv1.2 assembles as a tetramer, often with auxiliary subunits:
KvĪ² subunits: Modify kinetics and trafficking
KChiP proteins: Calcium sensor interactions
PSD-95 family: Scaffold protein interactions at synapses
Gene Structure
The KCNA2 gene is located on chromosome 1p13.3 and encodes a 499-amino acid transmembrane protein with six alpha-helical segments (S1-S6). The gene consists of multiple exons and undergoes alternative splicing to generate channel variants with distinct properties.
Protein Topology
The Kv1.2 protein contains:
S1-S4 voltage sensor domain: S4 helix carries positive charges
S5-S6 pore domain: Forms the ion conduction pathway
N-terminal domain: Mediates tetramerization and subunit interaction
C-terminal domain: Contains binding sites for regulatory proteins
Disease Associations
Epilepsy
KCNA2 mutations cause epilepsy through various mechanisms:
Developmental and epileptic encephalopathy: Dominant de novo mutations cause early-onset seizures
Ataxia and seizures: Associated with cerebellar dysfunction
Channel dysfunction: Both loss and gain of function mutations identified
Specific variants: A301V, V396L, and others linked to epileptic phenotypes
Ataxia
KCNA2 mutations cause cerebellar ataxia:
Impaired cerebellar neuron function
Gait and coordination difficulties
Often with associated epilepsy
Purkinje cell dysfunction contributes to ataxic symptoms
Intellectual Disability
KCNA2 in neurodevelopment:
Mutations cause intellectual disability
May affect circuit formation during development
Often with comorbid epilepsy
Variable severity depending on mutation type
Other Conditions
Migraine: Some KCNA2 variants associated with migraine susceptibility
Neuromuscular disorders: Rare associations with peripheral nerve hyperexcitability
Autism spectrum disorder: Possible involvement in neurodevelopmental conditions
Expression Pattern
KCNA2 is expressed in:
Hippocampal neurons (pyramidal cells) - high expression in CA1/CA3
Cerebellar Purkinje cells - critical for cerebellar circuit function
Cortical pyramidal neurons - layer 2/3 and layer 5
The study of Kcna2 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
Mastrangelo M, et al, "KCNA2-related disorders: expanded phenotypic spectrum and mechanisms." Neurology 2023 (2023)
Niday Z, et al, "KCNA2 mutations cause epilepsy and ataxia." Brain 2022 (2022)
Pan Z, et al, "Structure and function of Kv1.2 channels." Nature 2021 (2021)
Brewster AL, et al, "Kv1.2 in hippocampal epilepsy." J Neurosci 2020 (2020)
Liu PW, et al, "Therapeutic targeting of Kv1 channels." Pharmacol Rev 2019 (2019)